Search results for "Hydantoin"

showing 10 items of 14 documents

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Nov…

2017

Abstract Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. Here, we evaluate the activity of darolutamide in enzalutamide-resistant castration resistant prostate cancer (CRPC) as well as in AR mutants detected in patients after treatment with enzalutamide, abiraterone, or bicalutamide. Darolutamide significantly inhibited cell growth and AR transcriptional activity in enzalutamide-resistant MR49F cells in vitro, and led to decreased tumor volume and serum prostate-specific antigen l…

0301 basic medicineMaleModels MolecularTime FactorsTranscription GeneticProtein ConformationProstate cancerchemistry.chemical_compoundMice0302 clinical medicineMolecular Targeted TherapyTumor BurdenDarolutamideReceptors Androgen030220 oncology & carcinogenesisBenzamidesmedicine.drugSignal Transductionmedicine.medical_specialtyBicalutamideUrologyPartial agonist03 medical and health sciencesStructure-Activity RelationshipIn vivoInternal medicineCell Line TumorNitrilesPhenylthiohydantoinmedicineAndrogen Receptor AntagonistsEnzalutamideAnimalsHumansCell ProliferationDose-Response Relationship DrugCell growthbusiness.industryProstatic Neoplasmsmedicine.diseaseXenograft Model Antitumor AssaysAndrogen receptor030104 developmental biologyEndocrinologychemistryDrug Resistance NeoplasmMutationCancer researchPyrazolesbusinessEuropean urology
researchProduct

Prostaglandin D2 regulates joint inflammation and destruction in murine collagen-induced arthritis.

2012

Item does not contain fulltext OBJECTIVE: Prostaglandin D2 (PGD2) may exert proinflammatory or antiinflammatory effects in different biologic systems. Although this prostanoid and the enzymes responsible for its synthesis are up-regulated by interleukin-1beta (IL-1beta) in human chondrocytes in vitro, the role of PGD2 in arthritis remains unclear. This study was undertaken to investigate the role of PGD2 in the inflammatory response and in joint destruction during the development of collagen-induced arthritis (CIA) in mice. METHODS: PGD2 and cytokine levels in mice with CIA were determined by enzyme-linked immunosorbent assay. Expression of hematopoietic PGD synthase (h-PGDS), lipocalin-typ…

Agonistmusculoskeletal diseasesmedicine.medical_specialtyIndolesmedicine.drug_classmedicine.medical_treatmentChemokine CXCL1ImmunologyInterleukin-1betaReceptors ProstaglandinArthritisInflammationProinflammatory cytokinechemistry.chemical_compoundMiceRheumatologyBone MarrowInternal medicinemedicineImmunology and AllergyAnimalsPharmacology (medical)Receptors ImmunologicReceptorintegumentary systembusiness.industryProstaglandin D2Hydantoinsmedicine.diseaseArthritis ExperimentalLipocalinsHindlimbInterleukin-10Up-RegulationIntramolecular OxidoreductasesInterleukin 10CytokineEndocrinologychemistryMice Inbred DBACytokinesJointslipids (amino acids peptides and proteins)Prostaglandin D2Immune Regulation Auto-immunity transplantation and immunotherapy [NCMLS 2]medicine.symptombusiness
researchProduct

Multi-technique approach for qualitative and quantitative characterization of furazidin degradation kinetics under alkaline conditions

2016

Degradation of drug furazidin was studied under different conditions of environmental pH (11-13) and temperature (30-60°C). The novel approach of hybrid hard- and soft-multivariate curve resolution-alternating least squares (HS-MCR-ALS) method was applied to UV-vis spectral data to determine a valid kinetic model and kinetic parameters of the degradation process. The system was found to be comprised of three main species and best characterized by two consecutive first-order reactions. Furazidin degradation rate was found to be highly dependent on the applied environmental conditions, showing more prominent differences between both degradation steps towards higher pH and temperature. Complim…

Clinical BiochemistryAnalytical chemistryPharmaceutical ScienceHydantoin02 engineering and technologyDerivativeKinetic energy01 natural sciencesLeast squaresMass SpectrometrySpectral lineAnalytical ChemistryHydrolysischemistry.chemical_compoundUltraviolet visible spectroscopyDrug DiscoverySpectroscopyFuraginHydrolysis010401 analytical chemistryTemperatureHydrogen-Ion Concentration021001 nanoscience & nanotechnology0104 chemical sciencesKineticschemistryDegradation (geology)Spectrophotometry Ultraviolet0210 nano-technologyJournal of Pharmaceutical and Biomedical Analysis
researchProduct

Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects

2004

The advent of psychotherapeutic drugs has enabled management of mental illness and other neurological problems such as epilepsy in the general population, without requiring hospitalization. The success of these drugs in controlling symptoms has led to their widespread use in the vulnerable population of pregnant women as well, where the potential embryotoxicity of the drugs has to be weighed against the potential problems of the maternal neurological state. This review focuses on the developmental toxicity and neurotoxicity of five broad categories of widely available psychotherapeutic drugs: the neuroleptics, the antiepileptics, the antidepressants, the anxiolytics and mood stabilizers, an…

Drugmedicine.medical_specialtymedia_common.quotation_subjectPopulationDevelopmental toxicityserotonin-reuptake inhibitorsEpilepsyNeurochemicalmedicineAnimalsHumansprenatal phenytoin exposurePsychiatryeducationbeta-adrenergic-receptorsmedia_commonPharmacologyrat-brain developmentPsychotropic Drugseducation.field_of_studybusiness.industryMental DisordersNeurotoxicityBrainbeta-adrenergic-receptors; central-nervous-system; cerebellar granule cells; developing cerebral-cortex; fetal hydantoin syndrome; messenger-rna expression; prenatal phenytoin exposure; rat-brain development; serotonin-reuptake inhibitors; st-johns-wortmedicine.diseaseMental illnessdeveloping cerebral-cortexmessenger-rna expressionMoodcerebellar granule cellsMolecular Medicinecentral-nervous-systemPlant Preparationsst-johns-wortfetal hydantoin syndromebusiness
researchProduct

Synthesis, labelling and evaluation of hydantoin-substituted indole carboxylic acids as potential ligands for positron emission tomography imaging of…

2011

The N-methyl- d-aspartate (NMDA) receptor as a type of ionotropic glutamatergic receptors is essential for physiological processes such as learning, memory and synaptic plasticity. A glutamate-induced overactivation of these receptors, accompanied by increased intracellular calcium concentration, causes cell injury and leads to a large number of acute or chronic neurological disorders, such as stroke, trauma, Parkinson's disease and Alzheimer's disease. In an attempt to visualise the glutamatergic neurotransmission in vivo with positron emission tomography, novel fluoroethoxy- and methoxy-substituted reference compounds based on the lead structure of a hydantoin-substituted indole-2-carboxy…

Indole testStereochemistryOrganic ChemistryRadiosynthesisHydantoinBiochemistryAnalytical Chemistrychemistry.chemical_compoundGlycine bindingchemistryDrug DiscoveryNMDA receptorMoietyRadiology Nuclear Medicine and imagingReceptorSpectroscopyIonotropic effectJournal of Labelled Compounds and Radiopharmaceuticals
researchProduct

Hydantoin-substituted 4,6-dichloroindole-2-carboxylic acids as ligands with high affinity for the glycine binding site of the NMDA receptor.

2002

A novel series of C-3 substituted 4,6-dichloroindole-2-carboxylic acids was synthesized to investigate the influence of different hydrogen-bond donor and acceptor groups at this specific position on the affinity to the glycine site of the NMDA receptor. These novel 3-indolylmethyl derivatives with ring-open (amines, sulfonamides, amides, ureas) and cyclic substituents (imidazolidin-2-ones, (thio)hydantoins) led to the discovery that compounds bearing a hydantoin substituent at the C-3 position of the indole nucleus are the most promising ones. In this series the hydantoins, ureas, and imidazolidin-2-ones were identified as very potent inhibitors of the binding of the glycine site specific l…

IndolesStereochemistrySwineGlycineHydantoinThio-In Vitro TechniquesLigandsBinding CompetitiveReceptors N-Methyl-D-Aspartatechemistry.chemical_compoundMiceRadioligand AssayStructure-Activity RelationshipGlycine bindingSeizuresDrug DiscoveryAnimalsBinding siteGlycine receptorIndole testElectroshockBinding SitesBicyclic moleculeHydantoinsBrainRatschemistryGlycineMolecular MedicineAnticonvulsantsFemaleJournal of medicinal chemistry
researchProduct

The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study

2017

Background/Aim: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. Patients and Methods: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints. Results: Enzalutamide was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum levels of PSA before and after treatment was observed. A significant …

Male0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentDocetaxelKaplan-Meier Estimateurologic and male genital diseasesDrug resistantAntineoplastic Agentchemistry.chemical_compoundProstate cancer0302 clinical medicinePrednisoneClinical endpointProspective StudiesNeoplasm MetastasisProspective cohort studyAged 80 and overProstate cancerGeneral MedicineMiddle AgedNeoplasm MetastasiProstatic Neoplasms Castration-ResistantProstate-specific antigenTreatment OutcomeOncologyDocetaxel030220 oncology & carcinogenesisBenzamidesRegression AnalysisTaxoidsHumanmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaRegression Analysi03 medical and health sciencesTaxoidInternal medicineNitrilesPhenylthiohydantoinEnzalutamidemedicineChemotherapyHumansEnzalutamideAgedChemotherapybusiness.industryProstatic NeoplasmsProstate-Specific Antigenmedicine.diseaseProspective Studie030104 developmental biologychemistryDrug Resistance NeoplasmProstatic NeoplasmPrednisonebusinessAnticancer Research
researchProduct

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prosta…

2017

Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide. We obtained a clinically but not significant difference favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48, 95% CI 0.22–1.02). No signi…

Malemedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentUrologyAbiraterone AcetateBone NeoplasmsAbiraterone; Enzalutamide; mCRPC; rPFS; tSRE; Hematology; Oncology; Geriatrics and GerontologyPlaceboDisease-Free Survivallaw.invention03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineRandomized controlled triallawNitrilesPhenylthiohydantoinEnzalutamideAndrogen Receptor AntagonistsMedicineEnzalutamideCytochrome P-450 Enzyme InhibitorsHumans030212 general & internal medicineProgression-free survivalAbirateronetSRERandomized Controlled Trials as TopicChemotherapybusiness.industryAbiraterone acetateHematologymCRPCmedicine.diseaseProstatic Neoplasms Castration-ResistantTreatment OutcomechemistryDocetaxelrPFSOncology030220 oncology & carcinogenesisBenzamidesDisease ProgressionGeriatrics and Gerontologybusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct

Variations of acidic functions at position 2 and substituents at positions 4, 5 and 6 of the indole moiety and their effect on NMDA-glycine site affi…

2003

The synthetic procedures to obtain indole derivatives with different acidic functions at position 2 of the indole are reported. The synthesised and tested derivatives comprise 5-tetrazolyl, 1,3,4-oxadiazol-5-yl-2-one, and indole-2-carboxylic acid amides with 5-aminotetrazole, methanesulphonamide and trifluoromethanesulphonamide moieties. The binding affinity was evaluated using [3H]MDL 105,519 and pig cortical brain membranes. In general, compounds with acidic functions different from a carboxylic acid moiety are less potent than indole-2-carboxylic acid derivatives. Also, the 4,6-dichloro substitution pattern was compared to 5-tert-butyl derivatives and compounds not substituted in the ben…

Models MolecularIndolesSwineStereochemistryCarboxylic acidGlycineReceptors N-Methyl-D-AspartateChemical synthesisInhibitory Concentration 50Radioligand AssayStructure-Activity Relationshipchemistry.chemical_compoundDrug DiscoveryAnimalsMoietyBenzeneImideCerebral CortexPharmacologyIndole testchemistry.chemical_classificationBinding SitesBicyclic moleculeCell MembraneOrganic ChemistryGeneral MedicineLigand (biochemistry)MembranechemistryGlycineHydantoin derivativesNMDA receptorEuropean Journal of Medicinal Chemistry
researchProduct

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Pro…

2017

Abstract Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. Objective To confirm AR-V7 as a predictor of resistance to hormonal therapy and develop a new approach to assess AR-V7 by highly sensitive digital droplet polymerase chain reaction (ddPCR) in plasma-derived exosomal RNA. Design, setting, and participants Plasma samples were collected from 36 CRPC patients before they began second-line hormonal treatment. …

Oncology0301 basic medicineMaleResistanceExosomeschemistry.chemical_compoundProstate cancer0302 clinical medicineProtein IsoformsNeoplasm MetastasisReceptorAged 80 and overProstate cancerMiddle AgedProstatic Neoplasms Castration-ResistantReceptors Androgen030220 oncology & carcinogenesisBenzamidesAdenocarcinomaBiomarker (medicine)Hormonal therapyAR-V7; Digital droplet PCR; Exosomes; Hormonal therapy; Pharmacogenetics; Prostate cancer; Resistance; UrologyAndrostenesHormonal therapymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classUrologyCastration resistantAdenocarcinomaDisease-Free Survival03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicineNitrilesPhenylthiohydantoinmedicineEnzalutamideHumansAgedDigital droplet PCRPlasma derivedbusiness.industryRNAAndrogen Receptor Splice Variant 7medicine.diseaseAndrogenEndocrinology030104 developmental biologychemistryPharmacogeneticsDrug Resistance NeoplasmCancer cellCancer researchRNAAR-V7businessPharmacogenetics
researchProduct